ERAP1

Across TCGA pan-cancer cohorts, ERAP1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ERAP1 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ERAP1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ERAP1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LSCC are the cancer types where ERAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.974	0.702	.001	45	view →
GBM	OS	Tertile	All	0.587	0.227	.008	15	view →
LSCC	OS	Tertile	II,III,IV	0.543	0.914	.002	11	view →
HNSC	OS	Median	III,IV	1.000	0.484	.038	8	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
CCRCC	DFS	Quartile	III,IV	0.246	0.574	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ERAP1–PDAC (DFS)

Open the PDAC breakdown →